{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T20:39:28Z","timestamp":1777927168500,"version":"3.51.4"},"reference-count":21,"publisher":"Georg Thieme Verlag KG","issue":"01","license":[{"start":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T00:00:00Z","timestamp":1763856000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World J Nucl Med"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Metachronous malignancies carry poor prognosis and pose certain challenges for management of two different malignancies simultaneously. A 59-year-old male, a patient of ALK+ lung adenocarcinoma demonstrating excellent initial response to targeted therapy with ALK inhibitor ceritinib, developed prostatic adenocarcinoma with neuroendocrine differentiation 36 months later, which was treated with abiraterone and leuprolide. Dual-tracer positron emission tomography (PET) imaging with 18F-FDG-PET\/computed tomography (CT) and 68Ga-PSMA-11 PET\/CT showed complete response of prostatic adenocarcinoma with controlled serum prostate-specific antigen level, showed new-onset metastatic brain and liver lesions 12 months later, the biopsy of the later revealed metastatic small cell neoplasia. The clinical profile, dual tracer PET\/CT and immunohistochemistry correlation assisted in concluding that prostate adenocarcinoma had transformed into small cell type, which metastasized to liver, whereas the lung adenocarcinoma had metastasized to brain.<\/jats:p>","DOI":"10.1055\/s-0045-1813675","type":"journal-article","created":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T23:30:17Z","timestamp":1763940617000},"page":"075-079","source":"Crossref","is-referenced-by-count":0,"title":["Small Cell Transformation of Metachronous ALK\u2009+\u2009ve Lung and Prostatic Adenocarcinoma following Initial Response to Ceritinib and Androgen Deprivation Therapies and Metastases to Two Different Organs: Guidance through FDG-PET\/CT and 68Ga-PSMA-11 PET\u2013CT and Biopsy\u2013Immunohistochemistry Correlation"],"prefix":"10.1055","volume":"25","author":[{"given":"Rangat","family":"Bagasariya","sequence":"additional","affiliation":[{"name":"Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Hospital Annexe, Mumbai, Maharashtra, India"},{"name":"Homi Bhabha National Institute, Mumbai, Maharashtra, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keerti","family":"Sitani","sequence":"additional","affiliation":[{"name":"Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Hospital Annexe, Mumbai, Maharashtra, India"},{"name":"Homi Bhabha National Institute, Mumbai, Maharashtra, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trupti","family":"Pai","sequence":"additional","affiliation":[{"name":"Homi Bhabha National Institute, Mumbai, Maharashtra, India"},{"name":"Department of Pathology, Tata Memorial Hospital, Mumbai, Maharashtra, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6607-2558","authenticated-orcid":false,"given":"Sandip","family":"Basu","sequence":"additional","affiliation":[{"name":"Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Hospital Annexe, Mumbai, Maharashtra, India"},{"name":"Homi Bhabha National Institute, Mumbai, Maharashtra, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2025,11,23]]},"reference":[{"issue":"01","key":"ref1","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/00000421-200302000-00015","article-title":"Multiple primary malignant neoplasms: case report and a comprehensive review of the literature","volume":"26","author":"C GN Demandante","year":"2003","journal-title":"Am J Clin Oncol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2147\/CLEP.S69718","article-title":"Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors","volume":"6","author":"P L Chia","year":"2014","journal-title":"Clin Epidemiol"},{"issue":"26","key":"ref3","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1200\/JCO.2009.22.6993","article-title":"Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK","volume":"27","author":"A T Shaw","year":"2009","journal-title":"J Clin Oncol"},{"issue":"09","key":"ref4","first-page":"1241","article-title":"Updated efficacy and safety data for ALTA-1L: brigatinib vs crizotinib in ALK+ NSCLC","volume":"13","author":"D R Camidge","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"23","key":"ref5","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"B J Solomon","year":"2014","journal-title":"N Engl J Med"},{"issue":"04","key":"ref6","first-page":"517","article-title":"Lorlatinib in advanced ALK-positive NSCLC after second-generation ALK TKI failure","volume":"21","author":"A T Shaw","year":"2020","journal-title":"Lancet Oncol"},{"issue":"06","key":"ref7","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/PAS.0000000000000208","article-title":"Proposed morphologic classification of prostate cancer with neuroendocrine differentiation","volume":"38","author":"J I Epstein","year":"2014","journal-title":"Am J Surg Pathol"},{"issue":"27","key":"ref8","first-page":"3379","article-title":"Active surveillance program for prostate cancer: an update","volume":"33","author":"J J Tosoian","year":"2015","journal-title":"J Clin Oncol"},{"issue":"9718","key":"ref9","first-page":"1428","article-title":"Postoperative radiotherapy after radical prostatectomy: EORTC trial","volume":"375","author":"M Bolla","year":"2010","journal-title":"Lancet"},{"key":"ref10","first-page":"1163","article-title":"Addition of docetaxel to ADT in mHSPC (STAMPEDE Trial)","volume":"389","author":"N D James","year":"2017","journal-title":"Lancet"},{"issue":"21","key":"ref11","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone in mCRPC","volume":"364","author":"J S de Bono","year":"2010","journal-title":"N Engl J Med"},{"issue":"12","key":"ref12","first-page":"1091","article-title":"VISION trial: 177Lu-PSMA-617 in mCRPC","volume":"385","author":"O Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0140-6736(17)30123-X","article-title":"First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study","volume":"389","author":"J C Soria","year":"2017","journal-title":"Lancet"},{"issue":"07","key":"ref14","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S1470-2045(17)30339-X","article-title":"Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial","volume":"18","author":"A T Shaw","year":"2017","journal-title":"Lancet Oncol"},{"issue":"05","key":"ref15","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1158\/2767-9764.CRC-21-0156","article-title":"Comprehensive assessment of anaplastic lymphoma kinase in localized and metastatic prostate cancer reveals targetable alterations","volume":"2","author":"R A Patel","year":"2022","journal-title":"Cancer Res Commun"},{"issue":"04","key":"ref16","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nrurol.2014.21","article-title":"Small cell carcinoma of the prostate","volume":"11","author":"R Nadal","year":"2014","journal-title":"Nat Rev Urol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"937713","DOI":"10.3389\/fonc.2022.937713","article-title":"Case report: 18F-PSMA PET\/CT scan in castration resistant prostate cancer with aggressive neuroendocrine differentiation","volume":"12","author":"M Bergamini","year":"2022","journal-title":"Front Oncol"},{"issue":"08","key":"ref18","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1097\/PAS.0b013e3181e6cbf3","article-title":"NKX3.1 as a marker of prostatic origin in metastatic tumors","volume":"34","author":"B Gurel","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"543272","DOI":"10.1155\/2011\/543272","article-title":"Review of small cell carcinomas of the prostate","volume":"2011","author":"P Furtado","year":"2011","journal-title":"Prostate Cancer"},{"issue":"01","key":"ref20","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13000-021-01096-1","article-title":"Clinicopathologic features of metastatic small cell carcinoma of the prostate to the liver: a series of four cases","volume":"16","author":"P D Bell","year":"2021","journal-title":"Diagn Pathol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"108436","DOI":"10.1016\/j.lungcan.2025.108436","article-title":"Brain metastases and mortality in patients with ALK + metastatic non-small cell lung cancer treated with second-generation ALK tyrosine kinase inhibitors as first-line targeted therapies: an observational cohort study","volume":"201","author":"D Uprety","year":"2025","journal-title":"Lung Cancer"}],"container-title":["World Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0045-1813675.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T22:36:44Z","timestamp":1777675004000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0045-1813675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,23]]},"references-count":21,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2026,5,1]]},"published-print":{"date-parts":[[2026,3]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0045-1813675","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["1450-1147","1607-3312"],"issn-type":[{"value":"1450-1147","type":"print"},{"value":"1607-3312","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,23]]}}}